NAD+
Nicotinamide adenine dinucleotide, a redox coenzyme and the substrate consumed by sirtuins, PARPs and CD38. Not a peptide.
For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Untreated baseline
- Validated pathway control
- Parallel viability measurement
Reported protocol
- Concentration target
- 100 mg/mL to 200 mg/mL
- Standard
- 50 mg to 100 mg daily, or 2 to 3 times per week
- Loading
- 50 mg daily for 10 consecutive days
- Route
- Subcutaneous or intramuscular
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Compound-specific: NAD+ solutions are pH-sensitive and degrade faster in alkaline conditions. Prepare fresh and check the pH of the final buffer rather than assuming it.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 2 mL | 250 mg/mL | 25 mg | 2500 mcg |
| 3 mL | 166.67 mg/mL | 16.67 mg | 1666.67 mcg |
| 5 mL | 100 mg/mL | 10 mg | 1000 mcg |
| 10 mL | 50 mg/mL | 5 mg | 500 mcg |